biostudies-literatureEnglish JDNHLBI NIH HHSUniversity of Michigan Office of the Provost MCube3.010742484221140303https://www.ebi.ac.uk/biostudies/studies/S-EPMC9841513biostudies-literatureUnknown27<h4>Background</h4>Despite advances in treatments, myocardial infarction (MI) remains a significant cause of morbidity and mortality worldwide. Our team has previously shown that valproic acid (VPA) is cardio-protective when administered to rats post-MI. The aim of this study was to investigate the association of VPA use with post-MI heart failure (HF) development in humans.<h4>Methods</h4>This study was a random effects meta-analysis of two retrospective case-control studies collected from electronic health record (Michigan Medicine) and claims data (OptumInsight). Cases with an active prescription for VPA at the time of their MI were matched 1:4 to controls not taking VPA at the time of their MI by multiple demographic and clinical characteristics. The primary outcome, time-to-HF developJournal of cardiovascular pharmacology and therapeuticsAssociation of Valproic Acid Use With Post-Myocardial Infarction Heart Failure Development: A Meta-Analysis of Two Retrospective Case-Control Studies.PMC9841513K08 HL146990R01 HL163672U064172R01 HL139735English JDTian SLuzum JAWang ZfalseAssociation of Valproic Acid Use With Post-Myocardial Infarction Heart Failure Development: A Meta-Analysis of Two Retrospective Case-Control Studies.<h4>Background</h4>Despite advances in treatments, myocardial infarction (MI) remains a significant cause of morbidity and mortality worldwide. Our team has previously shown that valproic acid (VPA) is cardio-protective when administered to rats post-MI. The aim of this study was to investigate the association of VPA use with post-MI heart failure (HF) development in humans.<h4>Methods</h4>This study was a random effects meta-analysis of two retrospective case-control studies collected from electronic health record (Michigan Medicine) and claims data (OptumInsight). Cases with an active prescription for VPA at the time of their MI were matched 1:4 to controls not taking VPA at the time of their MI by multiple demographic and clinical characteristics. The primary outcome, time-to-HF develop2022-01-01T00:00:00Z2022 Jan-Dec2025-04-04T00:02:55.177Z2025-04-04T00:02:55.177ZS-EPMC98415133641639210.1177/10742484221140303